Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHX1LA)

Drug Name
KL001 Drug Info
Synonyms
309928-48-1; N-(3-(9H-carbazol-9-yl)-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-hydroxypropyl)-N-(furan-2-ylmethyl)methanesulfonamide; SMR000106264; MLS000110334; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; KL-001; N-[3-(9H-Carbazol-9-yl)-2-hydroxypropyl]-N-[(furan-2-yl)methyl]methanesulfonamide; N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-(furan-2-ylmethyl)methanesulfonamide; CBMicro_005790; ChemDiv2_003790; Oprea1_152161; Oprea1_419357; MLS002540427; MLS006011739; CHEMBL1498001; SCHEMBL15380452; BDBM56256; cid_2888648; HMS1379M06; HMS2371E17; SMSF0015860; STK839587; AKOS000581142; AKOS016386481; CB08282; MCULE-8116422943; IDI1_002505; NCGC00079434-02; NCGC00079434-03; NCGC00079434-06; BIM-0006034.P001; KL001(KL-001;KL 001); EU-0005302; ST50257205; 10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; doi:10.14272/OQAFDLPAPSSOHY-UHFFFAOYSA-N; SR-01000436091; SR-01000436091-1; BRD-A94580299-001-08-8; F1345-0456; (3-carbazol-9-yl-2-hydroxypropyl)(2-furylmethyl)(methylsulfonyl)amine; N-(3-carbazol-9-yl-2-hydroxy-propyl)-N-(2-furfuryl)methanesulfonamide; N-[3-(9-carbazolyl)-2-hydroxypropyl]-N-(2-furanylmethyl)methanesulfonamide; N-(3-carbazol-9-yl-2-oxidanyl-propyl)-N-(furan-2-ylmethyl)methanesulfonamide
Indication
Disease Entry ICD 11 Status REF
Glioblastoma of brain 2A00.00 Preclinical [1]
Cross-matching ID
PubChem CID
2888648
TTD Drug ID
DMHX1LA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Preclinical Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cryptochrome circadian clock 1 (CRY1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Ethoxypropanoic acid DMAM4FE Breast cancer 2C60-2C65 Preclinical [3]
SHP656 DM8DYJQ Glioblastoma of brain 2A00.00 Preclinical [1]
TH301 DM4BDGW Glioblastoma of brain 2A00.00 Preclinical [1]
KL044 DMG3FDE Discovery agent N.A. Investigative [4]
Drug(s) Targeting Cryptochrome-2 (CRY2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-Ethoxypropanoic acid DMAM4FE Breast cancer 2C60-2C65 Preclinical [3]
SHP656 DM8DYJQ Glioblastoma of brain 2A00.00 Preclinical [1]
TH301 DM4BDGW Glioblastoma of brain 2A00.00 Preclinical [1]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cryptochrome circadian clock 1 (CRY1) TT5MLZR CRY1_HUMAN Activator [2]
Cryptochrome-2 (CRY2) TTAO58M CRY2_HUMAN Activator [2]

References

1 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
2 Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7.
3 The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55.
4 Development of Small-Molecule Cryptochrome Stabilizer Derivatives as Modulators of the Circadian Clock. ChemMedChem. 2015 Sep;10(9):1489-97.